Jens Mogensen

List of Publications by Year
in descending order

61 papers	12,932 citations	94433 37 h-index	123424 61 g-index
65 all docs	65 docs citations	65 times ranked	12197 citing authors

#	Article	IF	Citations
1	The role of the electrocardiographic phenotype in risk stratification for sudden cardiac death in childhood hypertrophic cardiomyopathy. European Journal of Preventive Cardiology, 2022, 29, 645-653.	1.8	20
2	Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis registry. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 9, 42-53.	4.0	11
3	Importance of genotype for risk stratification in arrhythmogenic right ventricular cardiomyopathy using the 2019 ARVC risk calculator. European Heart Journal, 2022, 43, 3053-3067.	2.2	41
4	Relationship Between Maximal Left Ventricular Wall Thickness and Sudden Cardiac Death in Childhood Onset Hypertrophic Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2022, 15, CIRCEP121010075.	4.8	8
5	Clinical Features and Natural History of Preadolescent Nonsyndromic HypertrophicÂCardiomyopathy. Journal of the American College of Cardiology, 2022, 79, 1986-1997.	2.8	20
6	Prospective follow-up in various subtypes of cardiomyopathies: insights from the ESC EORP Cardiomyopathy Registry. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 134-142.	4.0	3
7	Prevalence and clinical outcomes of dystrophinâ€associated dilated cardiomyopathy without severe skeletal myopathy. European Journal of Heart Failure, 2021, 23, 1276-1286.	7.1	14
8	1â€...The role of the electrocardiographic phenotype in risk stratification for sudden cardiac death in childhood hypertrophic cardiomyopathy. , 2021, , .		2
9	Association of Left Ventricular Systolic Dysfunction Among Carriers of Truncating Variants in Filamin C With Frequent Ventricular Arrhythmia and End-stage Heart Failure. JAMA Cardiology, 2021, 6, 891.	6.1	36
10	Clinical and Genetic Investigations of 109 Index Patients With Dilated Cardiomyopathy and 445 of Their Relatives. Circulation: Heart Failure, 2020, 13, e006701.	3.9	12
11	Clinical Phenotypes and Prognosis of Dilated Cardiomyopathy Caused by Truncating Variants in the TTN Gene. Circulation: Heart Failure, 2020, 13, e006832.	3.9	75
12	Recessive Inheritance of a Rare Variant in the Nuclear Mitochondrial Gene for AARS2 in Late-Onset Dilated Cardiomyopathy. Circulation Genomic and Precision Medicine, 2020, 13, 560-562.	3.6	6
13	Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2020, 396, 759-769.	13.7	481
14	Clinical Profile of Cardiac Involvement in Danon Disease. Circulation Genomic and Precision Medicine, 2020, 13, e003117.	3.6	29
15	Clinical Features and Natural History of PRKAG2 Variant Cardiac Glycogenosis. Journal of the American College of Cardiology, 2020, 76, 186-197.	2.8	45
16	Development of a Novel Risk Prediction Model for Sudden Cardiac Death in Childhood Hypertrophic Cardiomyopathy (HCM Risk-Kids). JAMA Cardiology, 2019, 4, 918.	6.1	147
17	Pathogenic RBM20 -Variants Are Associated With a Severe Disease Expression in Male Patients With Dilated Cardiomyopathy. Circulation: Heart Failure, 2019, 12, e005700.	3.9	56
18	International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM). Circulation, 2018, 137, 1015-1023.	1.6	149

#	Article	IF	Citations
19	Formin Homology 2 Domain Containing 3 (FHOD3) Is a Genetic Basis for Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2018, 72, 2457-2467.	2.8	59
20	Dilated Cardiomyopathy DueÂtoÂBLC2-Associated AthanogeneÂ3Â(BAG3)ÂMutations. Journal of the American College of Cardiology, 2018, 72, 2471-2481.	2.8	93
21	The clinical outcome of LMNA missense mutations can be associated with the amount of mutated protein in the nuclear envelope. European Journal of Heart Failure, 2018, 20, 1404-1412.	7.1	12
22	DOK7 congenital myasthenia may be associated with severe mitral valve insufficiency. Journal of the Neurological Sciences, 2017, 379, 217-218.	0.6	3
23	A mutation in the glutamate-rich region of RNA-binding motif protein 20 causes dilated cardiomyopathy through missplicing of titin and impaired Frankâ€“Starling mechanism. Cardiovascular Research, 2016, 112, 452-463.	3.8	97
24	Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. European Heart Journal, 2016, 37, 1850-1858.	2.2	757
25	European Cardiomyopathy Pilot Registry: EURObservational Research Programme of the European Society of Cardiology. European Heart Journal, 2016, 37, 164-173.	2.2	56
26	A Systematic Review of Phenotypic Features Associated With Cardiac Troponin I Mutations in Hereditary Cardiomyopathies. Canadian Journal of Cardiology, 2015, 31, 1377-1385.	1.7	37
27	The current role of next-generation DNA sequencing in routine care of patients with hereditary cardiovascular conditions: a viewpoint paper of the European Society of Cardiology working group on myocardial and pericardial diseases and members of the European Society of Human Genetics. European Heart Journal, 2015, 36, 1367-1370.	2.2	75
28	The TMEM43 Newfoundland mutation p.S358L causing ARVC-5 was imported from Europe and increases the stiffness of the cell nucleus. European Heart Journal, 2015, 36, 872-881.	2.2	56
29	Atlas of the clinical genetics of human dilated cardiomyopathy. European Heart Journal, 2015, 36, 1123-1135.	2.2	456
30	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. European Heart Journal, 2014, 35, 2733-2779.	2.2	3,469
31	Triage strategy for urgent management of cardiac tamponade: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2014, 35, 2279-2284.	2.2	154
32	Truncating Plakophilin-2 Mutations in Arrhythmogenic Cardiomyopathy Are Associated With Protein Haploinsufficiency in Both Myocardium and Epidermis. Circulation: Cardiovascular Genetics, 2014, 7, 230-240.	5.1	36
33	Mutated Desmoglein-2 Proteins are Incorporated into Desmosomes and Exhibit Dominant-Negative Effects in Arrhythmogenic Right Ventricular Cardiomyopathy. Human Mutation, 2013, 34, 697-705.	2.5	30
34	The LMNA mutation p.Arg321Ter associated with dilated cardiomyopathy leads to reduced expression and a skewed ratio of lamin A and lamin C proteins. Experimental Cell Research, 2013, 319, 3010-3019.	2.6	23
35	Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2013, 34, 1448-1458.	2.2	346
36	Clinical utility gene card for: Dilated Cardiomyopathy (CMD). European Journal of Human Genetics, 2013, 21, 1185-1185.	2.8	30

#	Article	IF	Citations
37	Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2013, 34, 2636-2648.	2.2	2,436
38	Genderâ€specific differences in major cardiac events and mortality in lamin A/C mutation carriers. European Journal of Heart Failure, 2013, 15, 376-384.	7.1	120
39	Long-Term Outcomes in Hypertrophic Cardiomyopathy Caused by Mutations in the Cardiac Troponin T Gene. Circulation: Cardiovascular Genetics, 2012, 5, 10-17.	5.1	103
40	Risk Factors for Malignant Ventricular Arrhythmias in Lamin A/C Mutation Carriers. Journal of the American College of Cardiology, 2012, 59, 493-500.	2.8	449
41	Quantitative Expression of the Mutated Lamin A/C Gene in Patients With Cardiolaminopathy. Journal of the American College of Cardiology, 2012, 60, 1916-1920.	2.8	34
42	Left ventricular longitudinal systolic function after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a long-term follow-up study focused on speckle tracking echocardiography. European Journal of Echocardiography, 2010, 11, 883-888.	2.3	9
43	Restrictive cardiomyopathy. Current Opinion in Cardiology, 2009, 24, 214-220.	1.8	74
44	Prevalence, Clinical Significance, and Genetic Basis of Hypertrophic Cardiomyopathy With Restrictive Phenotype. Journal of the American College of Cardiology, 2007, 49, 2419-2426.	2.8	167
45	Troponin Mutations in Cardiomyopathies. , 2007, 592, 201-226.		2
46	Functional effects of the DCM mutant Gly159Asp Troponin C in skinned muscle fibres. Pflugers Archiv European Journal of Physiology, 2007, 453, 771-776.	2.8	18
47	Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. European Heart Journal, 2006, 27, 1933-1941.	2.2	352
48	Actin mutations in hypertrophic and dilated cardiomyopathy cause inefficient protein folding and perturbed filament formation. FEBS Journal, 2005, 272, 2037-2049.	4.7	71
49	Novel Mutation in Desmoplakin Causes Arrhythmogenic Left Ventricular Cardiomyopathy. Circulation, 2005, 112, 636-642.	1.6	266
50	Dilated Cardiomyopathy Mutations in Three Thin Filament Regulatory Proteins Result in a Common Functional Phenotype. Journal of Biological Chemistry, 2005, 280, 28498-28506.	3.4	133
51	Current approaches to unravel the mystery of dilated cardiomyopathy, a common cause of hereditary heart failure. Expert Review of Proteomics, 2005, 2, 827-830.	3.0	0
52	Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome. Journal of the American College of Cardiology, 2005, 45, 922-930.	2.8	155
53	Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 2004, 44, 2315-2325.	2.8	124
54	Severe disease expression of cardiac troponin C and T mutations in patients with idiopathic dilated cardiomyopathy. Journal of the American College of Cardiology, 2004, 44, 2033-2040.	2.8	216

#	Article	IF	Citations
55	Novel mutation in cardiac troponin I in recessive idiopathic dilated cardiomyopathy. Lancet, The, 2004, 363, 371-372.	13.7	162
56	Genomic structure of the human mitochondrial chaperonin genes: HSP60 and HSP10 are localised head to head on chromosome 2 separated by a bidirectional promoter. Human Genetics, 2003, 112, 71-77.	3.8	131
57	Hypertrophic cardiomyopathyâ€"the clinical challenge of managing a hereditary heart condition. European Heart Journal, 2003, 24, 496-498.	2.2	6
58	Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. Journal of Clinical Investigation, 2003, 111, 209-216.	8.2	169
59	Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. Journal of Clinical Investigation, 2003, 111, 209-216.	8.2	278
60	Î±-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. Journal of Clinical Investigation, 1999, 103, R39-R43.	8.2	353
61	An improved method for chromosome-specific labeling of Î± satellite DNA in situ by using denatured double-stranded DNA probes as primers in a primed in situ labeling (PRINS) procedure. Genetic Analysis, Techniques and Applications, 1991, 8, 171-178.	1.5	59